Literature DB >> 16819509

Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis.

P Laiho1, A Kokko, S Vanharanta, R Salovaara, H Sammalkorpi, H Järvinen, J-P Mecklin, T J Karttunen, K Tuppurainen, V Davalos, S Schwartz, D Arango, M J Mäkinen, L A Aaltonen.   

Abstract

Serrated colorectal carcinomas (CRCs) are morphologically different from conventional CRCs and have been proposed to follow a distinct pathway of CRC formation. Despite studies of single molecular events in this tumor type, the diagnosis of serrated CRC relies on morphology and the putative unique biological character of these tumors has not been established. Here we show that the gene expression profiling of 37 CRCs separated serrated and conventional CRCs into two distinct branches in unsupervised hierarchical clustering (P-value 7.8 x 10(-7)), and revealed 201 differentially expressed genes representing potential biomarkers for serrated CRC. Immunohistochemistry was utilized to verify the key findings in the 37 CRCs examined by expression profiling, and a separate validation set of 37 serrated and 86 conventional CRCs was examined to evaluate the candidate biomarkers in an extended sample material. Ephrin receptor B2, hypoxia-inducible factor 1-alpha and patched appeared as proteins important for genesis of serrated CRC. This study establishes serrated CRCs as a biologically distinct subclass of CRC and represents a step forward in the molecular classification of these cancers. The study also provides a platform to understand the molecular basis of serrated CRC and in long term may contribute to the development of specific treatment options for this tumor type.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16819509     DOI: 10.1038/sj.onc.1209778

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  Annexin A10 is a marker for the serrated pathway of colorectal carcinoma.

Authors:  Sara A Sajanti; Juha P Väyrynen; Päivi Sirniö; Kai Klintrup; Jyrki Mäkelä; Anne Tuomisto; Markus J Mäkinen
Journal:  Virchows Arch       Date:  2014-11-14       Impact factor: 4.064

Review 2.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

3.  Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance.

Authors:  Haoyan Chen; Jie Xu; Jie Hong; Ruqi Tang; Xi Zhang; Jing-Yuan Fang
Journal:  Mol Oncol       Date:  2014-06-02       Impact factor: 6.603

4.  The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.

Authors:  Sari Tuupanen; Mikko Turunen; Rainer Lehtonen; Outi Hallikas; Sakari Vanharanta; Teemu Kivioja; Mikael Björklund; Gonghong Wei; Jian Yan; Iina Niittymäki; Jukka-Pekka Mecklin; Heikki Järvinen; Ari Ristimäki; Mariachiara Di-Bernardo; Phil East; Luis Carvajal-Carmona; Richard S Houlston; Ian Tomlinson; Kimmo Palin; Esko Ukkonen; Auli Karhu; Jussi Taipale; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2009-06-28       Impact factor: 38.330

Review 5.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 6.  Serrated pathway: alternative route to colorectal cancer.

Authors:  Arpád V Patai; Béla Molnár; Zsolt Tulassay; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

7.  Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis.

Authors:  Maria Caruso; James Moore; Gregory J Goodall; Michelle Thomas; Stuart Phillis; Anna Tyskin; Glenice Cheetham; Nancy Lerda; Hiroyuki Takahashi; Andrew Ruszkiewicz
Journal:  Virchows Arch       Date:  2009-01-27       Impact factor: 4.064

8.  Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.

Authors:  Nelson Ung; Tracy L Putoczki; Stanley S Stylli; Irvin Ng; John M Mariadason; Timothy A Chan; Hong-Jian Zhu; Rodney B Luwor
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

9.  Robust multi-tissue gene panel for cancer detection.

Authors:  Joseph Irgon; C Chris Huang; Yi Zhang; Dmitri Talantov; Gyan Bhanot; Sándor Szalma
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

10.  Prediction and testing of biological networks underlying intestinal cancer.

Authors:  Vishal N Patel; Gurkan Bebek; John M Mariadason; Donghai Wang; Leonard H Augenlicht; Mark R Chance
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.